Wearable-derived digital mobility outcomes have potential clinical applications in dementia, yet technical validation of analytical pipelines in this population remains limited. This study evaluated the validity of the mobgap pipeline for estimating walking speed, initial contact detection, stride duration, caden...
Cameron Kirk, M. Bancroft, Diego Kaski et al.· Journal of NeuroEngineering...· 0 citations
Background Digital mobility outcomes (DMOs) have been cited as potential clinical endpoints for trials in Parkinson's disease (PD). Current evidence from the Mobilise-D consortium suggests that selected DMOs are technically valid, with emerging research on their clinical validity. However, regulatory qualification of D...
Jack Lumsdon, Ríona Mc Ardle, Megan Hanrahan et al.· Journal of Parkinson's Disea...· 0 citations
Reduced mobility and gait quality in GHA-PD highlight risks of functional decline and loss of independence and further research should investigate lifestyle, cultural, environmental and healthcare factors that might contribute to these disparities.
Metin Bicer, Cameron Kirk, M. Agoriwo et al.· Frontiers in Aging Neuroscie...· 0 citations
Wearable mobility monitoring was generally acceptable to people with PD and carers when it offered clear clinical value, fit easily into everyday life, and provided reassurance that remote monitoring would complement rather than replace clinical care.
Megan Hanrahan, Jack Lumsdon, C. Wilson et al.· Journal of Medical Internet...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.